Osteoarthritis (OA) is the most common form of arthritis and is associated with a high economic burden. Conventional pharmacologic agents are limited by their inability to alter disease progression and are associated with an adverse safety profile. A number of dietary supplements are marketed for treatment of OA. Glucosamine is one of the most commonly used supplements for OA and most research suggests that glucosamine sulfate can improve symptoms of pain related to OA, as well as slow disease progression in patients with OA of the knee. Chondroitin sulphate (CS) also appears to reduce OA symptoms and there is some evidence that CS may have a role as a structure-modifying agent in the management of patients with knee OA. Several other supplements are promoted for treating OA, such as methylsulfonylmethane, Perna canaliculus (green-lipped mussel), Zingiber officinale (ginger), Harpagophytum procumbens (devil's claw), Curcuma longa (turmeric), and Boswellia serrata (frankincense), but more evidence regarding long-term efficacy or safety are required.
IntrODUctIOn
Osteoarthritis (OA) is a degenerative joint disease characterised by joint pain and dysfunction caused by a progressive and irreversible loss of articular cartilage. 1 OA is the most common form of arthritis and the WHO estimates that as much as 40% of people over 70 years of age suffer from OA of the knee.
OA is associated with an extremely high economic burden, largely attributable to the effects of disability, comorbid disease, and the expense of treatment. 1 In Singapore, 17,000 disability adjusted life years (DALYs) lost are attributable to OA. 2 As our population ages, the burden of disease is likely to increase correspondingly.
Treatment of OA remains symptomatic and is meant to control pain, improve function and quality of life. 3 Current recommendations for the management of OA include a combination of non-pharmacological interventions (e.g. patient education, musclestrengthening exercises and weight reduction) and pharmacologic agents (oral and topical analgesic agents, nonsteroidal antiinflammatory drugs [NSAIDs] and intraarticular therapies such as corticosteroids and hyaluronan preparations). 2, 3 Surgery may also be an option for patients who do not have satisfactory improvement of pain and function with adequate non-pharmacological and pharmacological treatment. 2 Core outcome measures used to monitor the progression of OA and the effects of therapy include 1. pain, 2. physical function, 3. patient global assessment and 4. joint imaging. 4 Within the symptom severity domains, several validated measurement instruments commonly used are the visual analog scales (VAS), the Western Ontario McMasters Universities Osteoarthritis (WOMAC) Index and the Lequesne Functional Severity Index. 4 Whilst conventional pharmacologic agents are effective in relieving pain, they are associated with side effects. NSAIDs in particular may cause review Proceedings of Singapore Healthcare  Volume 19  Number 3  2010 gastrointestinal (GI) bleeding and cardiovascular risks (including hypertension and thrombotic events). 3 Hence, the perception of dietary supplements being "natural" and "safe" may be one of the most compelling reason why patients use them for treatment of OA. In addition, several supplements have shown to be at least as effective as NSAIDs at relieving the symptoms of OA, and preliminary evidence suggests several of these supplements may have a role in influencing the course of OA. 5 In Singapore, dietary supplements are not subjected to pre-market approvals and licensing for their importation, manufacture and sales. Although a guideline was introduced for the trade in dealing with dietary supplements, the onus of responsibility for safety and quality still rests with the dealers and sellers. 6 Hence, lack of conclusive information on the efficacy and safety, formulations, label claims and purity of preparations are some of the issues that need to be addressed when using dietary supplements as complementary or alternative therapy.
The purpose of this article is to review the available literature on the effectiveness and safety of dietary supplements commonly used in our clinical setting for the treatment of OA ( Table 1) . Searches were done using Natural Medicines Comprehensive Database, The Cochrane Library and PubMed.
Glucosamine
Glucosamine is an endogenous amino sugar that is required for the synthesis of glycoproteins and glycosaminoglycans. It is found in synovial fluids, tendons, ligaments, cartilage and other joint structures. Exogenous glucosamine is derived from marine exoskeletons of shrimps, lobsters and crabs or produced synthetically. Glucosamine stimulates the metabolism of chondrocytes in the articular cartilage and of synovial cells in the synovial fluids. Preliminary research suggests that glucosamine may have anti-inflammatory effect and reduce cartilage degradation. It appears to inhibit interleukin 1-beta, which stimulates the gene expression and protein synthesis of cyclooxygenase-2 (COX-2). 7
The symptomatic efficacy and structural management of glucosamine on OA have been evaluated in many clinical trials. Evidence from several randomised controlled trials (RCTs) and reviews are presented below.
The role of glucosamine in the management of OA was examined in a RCT undertaken by Reginster et al. 8 Two hundred and twelve patients with knee OA were randomly assigned to 1500mg glucosamine sulphate (GS) or placebo once daily for 3 years. The primary outcome for progression of OA was measured by (1) mean joint space loss (2) minimum joint space width (JSW). Symptoms were scored using WOMAC index. At treatment endpoint, the 106 patients on placebo were found to have a progressive joint space narrowing (JSN), with a mean joint space loss of -0.31mm (95% Cl -0.48 to -0.13). There was no significant mean joint space loss in the 106 patients on GS (-0.06mm; 95% CI -0.22 to 0.09). Similar results were reported with minimum JSN. Patients in the glucosamine arm also presented with better symptomatic outcome versus placebo as assessed by WOMAC score.
Similar results were observed in another study done by Pavella et al. 9 Both of these RCTs 8, 9 represent the first clinical evidence that long term use of glucosamine may modify the natural progression of knee OA.
In a retrospective assessment of the above RCTs, knee OA patients were contacted in a long term follow up on the incidence of total knee replacement. 8, 9 Two hundred and seventy five patients (131 formerly on placebo and 144 on GS) were interviewed for present evaluation and follow up for approximately 5 years. It was found that total knee replacement occurred in more than twice as many patients from the placebo group than those formerly receiving GS (14.5% vs. 6.3%; p<0.05), with a relative risk that was therefore 0.43% (95% confidence interval (CI): 0.2 -0.92). This study indicated that long term use of GS may prevent the natural progression of knee OA. 10 The Glucosamine Unum in Die (once-a-day) Efficacy (GUIDE) trial, was a 6-month randomised placebo-controlled, double-blind trial assessing the effects of GS (1500mg administered once daily) on the symptoms of knee OA. Three hundred and eighteen patients were enrolled in this trial in which acetaminophen was used as a side comparator. Patients were randomly assigned to receive GS 1,500 mg once daily (n = 106), acetaminophen 3 g/day (n = 108), or placebo (n = 104). The primary outcome assessing pain/discomfort was measured by the change in the Lequesne Functional Severity index. Secondary parameters included the WOMAC Index and response according to the Osteoarthritis Research Society International (OARSI) criteria. GS was found to be more effective than placebo in improving the Lequesne score (p<0.05) whilst the 2.7-point decrease with acetaminophen was not significantly different from that with placebo (p>0.05). Similar results were observed for the WOMAC index. The findings of this study indicated that GS at the once-daily dosage of 1,500 mg is more effective than placebo in treating knee OA symptoms. 11 The trials 9-11 mentioned above was funded by health supplement manufacturer Rottapharm. Glucosamine used from this manufacturer as Rotta preparation and glucosamine preparations from other manufacturers were referred as non-Rotta.
A recent study performed by Rozendaal et al 12 however, was not able to confirm a beneficial effect of a non-Rotta preparation of GS in patients hip OA. In this RCT, 222 patients with hip OA were assigned to 1500mg of GS or placebo daily for 2 years. Primary outcome measures were WOMAC pain and function scores over 24 months and JSN after 24 months. No clinical benefit was reported in the GS treatment group as measured by WOMAC pain and function. JSN also did not differ after 24 months (mean difference, -0.029 [CI, -0.122 to 0.064]).
The Glucosamine/Chondroitin Arthritis Intervention (GAIT) Trial was a large, double-blind, placebo and celecoxib-controlled study sponsored by National Institute of Health. There were two phases in this trial: a short-term study of 24 weeks, followed by a longer-term study of another 18 months. 13 In this study, 1583 patients with knee OA were randomised to receive glucosamine hydrochloride (500mg three times daily), chondroitin sulphate (CS) (400mg three times daily), combination of glucosamine/ chondroitin, celecoxib (200mg/day) or placebo. At week 24, response (defined as a 20% decrease in their WOMAC pain subscale from baseline) to glucosamine and CS alone or in combination were not significantly better than placebo. 13 However, for patients with moderate-to-severe pain at baseline, a significantly higher response rate was seen with combined therapy than with placebo (79.2% vs. 54.3%, p = 0.002). 13 After the 24 weeks study, 662 patients continued with their original assigned blinded treatment for up to 2 years. 14 A subgroup analysis was also performed on studies using the different preparations (Rotta vs non-Rotta) of glucosamine. 15 Studies evaluating the Rotta preparation found glucosamine was superior to placebo for pain (SMD -1.11; 95% CI -1.66 to -0.57) and function (Lequesne index SMD -0.47; 95% CI -0.82 to -0.12. WOMAC outcomes of pain and function showed a superiority of glucosamine over placebo only for the Rotta preparation of glucosamine. Two RCTs using the Rotta preparation showed that glucosmaine was able to slow radiological progression of OA of the knee over a 3-year period. 15 Despite extensive research on the role of glucosamine in management of knee OA, controversy on efficacy related to symptomatic and structural improvement continues. There are a few potential factors that may have relevance when interpreting the contradictory results of these clinical trials.
The questions left unanswered -whether there is any differences in efficacy between glucosamine salts, different preparations, and when used with other agents or in different subgroup?
Most trials evaluating the efficacy and safety of glucosamine in OA patients were conducted using the sulphate instead of the hydrochloride form. Clinical trials using GS usually reported better outcomes in patients with OA of the knee. [8] [9] [10] [11] Proceedings of Singapore Healthcare  Volume 19  Number 3  2010
In a multi-centre RCT of glucosamine hydrochloride/ sulphate conducted by Qiu GX et al. 16 glucosamine hydrochloride was found to be as effective and safe as GS in the treatment of knee OA patients. In the GAIT study, glucosamine hydrochloride was also found not to be significantly better than placebo. But, the most clinically relevant results were seen when glucosamine hydrochloride was taken with CS. [13] [14] This raises the question on the importance of the glucosamine salt with regards to the efficacy of glucosamine.
An evidence-based report into the use of complementary medicines to treat rheumatic diseases concluded that despite some mixed results, the majority of controlled studies of GS showed significant clinical benefit whereas the evidence for glucosamine hydrochloride was either unavailable or less convincing. 17 The different brands of GS used have also yield conflicting outcomes in the various clinical trials.
In the Cochrane Database Systematic Review, a subgroup analysis evaluating the Rotta preparation of GS was found to be superior to placebo in treatment of pain and functional impairment resulting from symptomatic OA. 15 In most European countries, glucosamine or chondroitin preparations are marketed as pharmaceuticals. These preparations however are marketed as nutraceuticals or health supplements in other countries. In Singapore, glucosamine and chondroitin preparations are classified as health supplements. Hence, they are subjected to less stringent control for their importation, manufacture, marketing and sales. In North America, varying quantities of glucosamine have been noted in surveys done on several nutraceuticals. 18 The safety profile of glucosamine has been well documented in most of the studies. Side effects are mild and include gastrointestinal bloating, heartburn and diarrhoea. Adverse effects reported were reversed upon discontinuation of treatment.
However, glucosamine should be use with caution in people with shellfish allergy, diabetic and asthmatic patients. 19 Adverse reactions resulting from glucosamine-warfarin interaction has been reported in Australia, Canada, Europe and United States. Although no local report has been received, health professionals are advised to monitor INR closely in patients on glucosamine or other dietary supplements. 20 Symptomatic efficacy described in multiple studies performed on GS support continued consideration in the OA therapeutic armamentarium. The most compelling evidence of a potential for inhibiting the progression of OA is also obtained with GS. Given the safety profile and evidence described, GS should be recommended for patients with knee OA who are considering alternatives to traditional OA treatment.
chondroitin
Chondroitin is an endogenous glycosaminoglycan found in cartilaginous tissues of most mammals. It serves as a substrate for the formation of the joint matrix structure. 21 Chondroitin is promoted as having chondroprotective, antiinflammatory and analgesic effects, either as a single agent or in combination with other ingredients in commercial products.
The role of CS in managing OA has attracted much interest over the past decades. Three RCTs evaluating the symptomatic efficacy and structural modifying effect of CS in knee OA patients have produced inconsistent results. [22] [23] [24] Symptomatic efficacy assessed using Lequesne index was reported in only one of the trial 22 Two of the trials evaluating the intermittent and long term use of CS respectively, reported favourable response in retarding the progression of knee OA patients. 22, 23 In the 2-year long term trial, patients in the CS arm reported no change for joint space loss. 22, 23 Uebelhart D et al. 22 randomised 120 patients with knee OA to receive either CS 800mg/day or placebo for two periods of 3 months during 1 year. Primary outcome measure was Lequesne's algo-functional index (AFI). Secondary outcome measures included VAS, walking time, global assessment, and paracetamol consumption. At treatment endpoint, statistically significant improvements were seen in the CS group compared with placebo for both primary and secondary outcome measures. Radiological progression at month 12 showed significantly decreased JSW in the placebo group with no change in the CS group. 22 In a 2 year RCT by Michel BA et. al. 23 , 300 patients with knee OA were randomly assigned to receive either 800 mg CS or placebo once daily. primary outcome measure was joint space loss over 2 years and secondary outcomes include pain and function. Patients receiving placebo was found to have progressive joint space loss of 0.14 +/-0.61 mm after 2 years (p = 0.001). However, no significant change in mean JSW was observed in CS group(0.00 +/-0.53 mm). 23 The study conducted by Mazieres B et. al. showed inconsistent results in patients receiving CS. 24 In this 24-week RCT, 307 patients with knee OA were randomised to receive CS (1 g/day) or placebo. Primary outcome criteria were pain on daily activities and Lequesne's Index. Secondary outcomes included the rate of responders according to the outcome measures in rheumatoid arthritis clinical trials of the Osteoarthritis Research Society International (OMERACT-OARSI) criteria, quality of life, patient's/physician's global assessments and carry-over effect after treatment. Compared with placebo, improvement in pain score was statistically significant for the CS group whilst improved function in the CS group did not reach statistical significance.
Monfort et al 25 reviewed 5 meta-analyses evaluating the effectiveness of CS in the symptomatic management of OA. Four of the meta-analyses showed significant effects of pain and function in the CS group compared to placebo. A reduction of analgesic co-medication and pain relief with 4 to 12 weeks of CS treatment was also reported in 2 of the meta-analyses. Another metaanalysis with a high degree of heterogeneity, reported a minimal symptomatic benefit of CS.26 Data provided by this review indicated that CS has a slight to moderate efficacy in the symptomatic treatment of OA. 25 A meta-analysis of CS as a structure-modifying drug for knee OA patients was evaluated by Hochberg MC et al. 27 Pooled results showed a small significant effect of CS on reduction in the rate decline in minimum joint space width (JSW) of 0.07mm/year (95% CI 0.03, 0.10) that corresponded to an effect size of 0.26 (95% CI 0.14, 0.38) (p<0.0001). Despite variations in the number of patients enrolled and techniques used to measure outcome, the results demonstrated that CS is effective for reducing the rate of decline in minimum JSW and may have a role as a structure-modifying agent in the management of OA. 27 A recent meta-analysis by Lee YH et al 27 assessing the structural effect of daily GS or CS in patients with knee OA has produced some beneficial results. No significant effect was seen versus control on minimum JSN after the first year of treatment for both glucosamine and CS. A small to moderate protective effect on minimum JSN (SMD 0.432, 95% CI 0.131-0.392, p<0.001) was observed after 3 years of GS treatment. CS reported a small but significant protective effect on minimum JSN after 2 years (SMD 0.261, 95% CI 0.235-0.628, p<0.001) Available data from this analysis showed that GS and CS may delay radiological progression of OA of the knee after daily administration for over 2 to 3 years. 28 A network meta-analysis conducted by Simon Wandel et al. 29 failed to show any benefit of GS, glucosamine hydrochloride, CS or its combination in the management of OA. The result of 10 selected trials was analysed; 6 trials (n=1104) compared glucosamine with placebo, 3 trials (n=1229 patients) compared CS with placebo, and one trial (n=1265) compared glucosamine hydrochloride, CS, and their combination with placebo. Findings from this network meta-analysis indicated that glucosamine, chondroitin, and their combination do not result in a relevant reduction of joint pain nor affect JSN compared to placebo. 29 Side effects of CS in most of the studies are mild and include nausea, epigastric pain and diarrhea. However, it should be used with caution in patients with asthma, prostate cancer or those at increased risk to prostate cancer. 21
Although some of the studies suggested that CS has slight to moderate symptomatic efficacy in as well as a potential role as a structure-modifying agent, the clinical relevance of the observed results has to be further evaluated. More studies are needed to confirm the role of CS in the management of OA.
Methylsulfonylmethane (MSM)
MSM is a naturally occurring compound found in some green plants, certain species of algae, fruits, vegetables, grains and human adrenal glands. It is an odourless metabolite of dimethylsulfoxide (DMSO) and in the body about 15% of ingested DMSO is converted to MSM. 7 MSM is promoted as having anti-inflammatory and analgesic effects, either as a single agent or in combination with other ingredients in commercial products In a pilot clinical trial, Kim LS et al 31 randomised 50 men and women with knee OA to MSM 3g or placebo twice daily. Outcomes was assessed using WOMAC Index, VAS, patient's physician global assessments (disease status, response to therapy) and SF-36 evaluation (overall health related quality of life). Compared to placebo, MSM produced significant reduction in pain and physical function impairment as well as improvement in performing activities of daily living (p<0.05) but no notable changes were found in WOMAC stiffness and aggregated total symptoms score. 31 In a 12-week, randomized, placebo-controlled study, 118 patients with mild to moderate OA were given either glucosamine 500mg, MSM 500mg, glucosamine and MSM or placebo capsules three times. At week 12, the mean pain index and swelling index decreased with glucosamine and MSM therapy, while the decrease in combination therapy was greater (p<0.05). Combination therapy also resulted in a statistically significant decrease in the Lequesne index. 32 A systematic review of the related nutritional supplements DMSO and MSM in the treatment of OA of the knee failed to produce definitive conclusion for either supplements. Although both MSM trials reported significant improvement in pain outcomes, methodological issues and concerns over optimal dosage and treatment period were highlighted. The data from these trials provide positive but not definitive evidence that MSM is superior to placebo in the treatment of mild to moderate OA of the knee. 33 MSM has been well tolerated in clinical trials and do not appear to cause side effects more often than placebo. As clinical trials have lasted for 12 weeks or less; more data are needed to assess longterm safety of MSM. More evidence on definitive efficacy, optimum dosage and long-term safety must be evaluated before MSM can gain a place in treatment of OA.
Perna canaliculus (Green-Lipped Mussel)
The mollusc Perna canaliculus is endemic to New Zealand, where it is commonly known as greenlipped mussel (GLM). The observation that the coastal Maori population who regularly consumes the mussel suffered less arthritis than their inland counterparts, led to the development of nutritional supplements (e.g. Seatone® and Lyprinol®) containing extracts of the mussel. 34, 35 GLM is made up of a complex mixture of longchain fatty acids, including polyunsaturated fatty acids (mainly omega-3 fatty acids), such as docosahexaenoic acid, eicosapentaenoic acid, eicosatetraenoic acid and palmitic acid. 35 The anti-inflammatory properties of GLM are largely associated with the omega-3 fatty acids, which reduces prostaglandin and leukotriene synthesis via inhibition of the lipoxygenase (LOX) and cyclooxygenase (COX) pathways. 34, 36 A systematic review of GLM in the treatment of OA identified 4 RCTs assessing GLM as an adjunctive treatment to conventional medication in mild to moderate OA. 34 Three were placebo-controlled and the remaining RCT compared the effects of two extracts of GLM (a powder form and lipid extract, Lyprinol®). These trials reported clinical benefits in the GLM treatment group as measured by VAS pain score, morning stiffness, Lequesne functional index, patient and physician global assessment.
These studies have reported a low incidence of adverse effects, generally consisting of GI symptoms (e.g. flatulence, epigastric discomfort, nausea). These may have been caused by the use of concomitant NSAIDs. 34 Although GLM has a plausible biological mechanism for its purported action, more evidence on effectiveness and long-term safety is needed.
Zingiber officinale (Ginger)
Ginger (Zingiber officinale) is a herbal supplement used by many to treat a variety of conditions, including, pregnancy-induced nausea and vomiting, motion sickness and arthritic conditions. 37 Ginger is thought to have anti-inflammatory effects, possibly by inhibiting COX and LOX. 37
Two manufacturer sponsored trials evaluating the effectiveness of ginger in patients with OA showed mixed results. 39, 40 In a 6-week, double blind study, 261 patients with OA of the knee and moderate-to-severe pain were randomised to ginger extract (255 mg twice daily) or placebo with acetaminophen allowed as rescue medication. 39 Of the 247 evaluable patients, the proportion of responders (defined as a reduction in knee pain on standing of ≥ 15 mm on a VAS) was higher in the ginger extract group compared with the control group (63% versus 50%; p<0.05).
However, results from a randomized, placebocontrolled, crossover study comparing ginger extract (170 mg three times daily) and ibuprofen (400 mg three times daily) in 75 patients with OA of the hip or knee, showed only significant improvement in symptoms for both the ginger and ibuprofen groups before crossover.40 No significant difference between placebo and ginger extract could be demonstrated at the end of the study.
Ginger is usually well tolerated. Common side effects of ginger include abdominal discomfort, heartburn and diarrhea. 39, 40 However, more evidence of efficacy is needed before it can gain a place in treatment guidelines.
Harpagophytum procumbens (Devil's claw)
Extracts of the secondary roots of devil's claw (Harpagophytum procumbens) have been used for variety of traditional indications. In recent years, it has been commonly used as an anti-inflammatory and analgesic preparation for the relief of arthritic symptoms. The major active ingredient found to be responsible for its' anti-inflammatory activity is the harpagoside. 41 Several studies using various preparations of Harpagophytum procumbens in patients with OA have been published. Evidence of effectiveness was better with products containing at least 50 mg of harpagoside in the daily dosage than with those containing less. 41 Two studies evaluating an aqueous extract of devil's claw (Doloteffin®) taken at dose equivalent to 60 mg or 50 mg of harpagoside daily for 8 to 12 weeks showed improvement in pain scores compared to baseline. 42, 43 Chantre et al 44 From current data, devil's claw appears to be safe and side effects are usually limited to diarrhea and GI upset. 41, 44 Although current evidence suggest that devil's claw may be a beneficial supplement for treatment of OA, more evidence on effectiveness and long-term safety is needed before it can be recommended.
curcuma longa (turmeric)
The rhizome of turmeric (Curcuma longa) is traditionally used in Asian medicine as an antiinflammatory agent, a treatment for digestive disorders, and to enhance wound healing. 45 The principal active constituent of turmeric and the one responsible for its vibrant yellow colour is curcumin. 46 In vitro and in vivo studies have shown that curcumin inhibits a number of molecular targets involved in inflammation, including, COX-2, LOX, and inducible nitric oxide synthase (iNOS) enzymes. 46, 47 There have been few studies investigating the efficacy of curcumin for treatment of OA in humans. A recent 6-week study compared the efficacy of turmeric extract (2g/day) with ibuprofen (800 mg/ day) in 107 patients with knee OA. 48 Improvements in pain score and knee function were observed in both groups when compared to baseline at weeks 2, 4 and 6. However, turmeric extract appeared to be similarly efficacious when compared to ibuprofen for the treatment of knee OA.
Turmeric is generally well tolerated. It may cause GI side effects such as nausea and diarrhea. Existing data from published in vitro and in vivo studies suggest that curcumin may be a beneficial complementary treatment for OA. However, until more clinical trials are done, turmeric is not recommended for OA.
boswellia serrata (Frankincense)
Boswellia serrata (frankincense) is an ayurvedic herb that is purported to exhibit analgesic, antiinflammatory and anti-arthritic activity. 49 The major active ingredient of Bowewellia extract, Boswellic acid, has been shown to inhibit pro-inflammatory processes by their effects on LOX and COX and on the complement system. 50 Proceedings of Singapore Healthcare  Volume 19  Number 3  2010 A systematic review of Boswellia serrata identified 3 RCTs assessing its efficacy in the treatment of OA.50 Of these, 2 were placebo-controlled and 1 compared Boswellia with COX-2 inhibitor, valdecoxib. Both placebo -controlled trials demonstrated significant improvement in pain and function in the Boswellia group from baseline compared with placebo. 51, 52 Results from the 6-month study comparing Boswellia with valdecoxib in 66 patients with OA of the knee showed that patients in both treatment groups experience significant improvements in pain. However, though Boswellia showed a slower onset of action, the effect persisted even after stopping therapy for one month whilst the effect of valdecoxib only persisted for as long as the treatment was continued. 50, 53 Boswellia serrata was generally well tolerated in clinical trials with side effects usually limited to diarrhoea, abdominal pain, and nausea. [46] [47] [48] [49] Although current evidence may be encouraging, larger RCTs are needed before Boswellia can be recommended for the treatment of OA.
cOncLUSIOn
The search for effective dietary supplements as an adjunct treatment of OA is a long continuous process. A minor difference in protocol often results in differing and confusing information. Nevertheless, based on current knowledge we would conclude that;
Although the evidence of glucosamine is not entirely consistent, most research suggests that GS can improve symptoms of pain related to OA, as well as slow disease progression in patients with OA of the knee.
CS appears to reduce OA symptoms and has a potential in the structural management of OA. The clinical relevance of the observed results however, has to be further evaluated. More studies are needed to confirm the role of CS in the management of OA.
Several other supplements are promoted for treating OA, such as MSM, devil's claw, turmeric, ginger etc., but more evidence on long-term safety or effectiveness is needed before they can gain a place in the treatment of OA.
reFerenceS:

